A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out the advertisement of prescriptions for injectable weight-loss drugs without ...

More and more Americans are turning to GLP-1 injections to lose weight. FOX 7 Austin's Rebecca Thomas spoke to an Austin physician to discuss.

A once weekly injection of semaglutide, the main ingredient in Ozempic and Wegovy, may help problem drinkers kick their cravings. In a new study, the drug, known for treating type 2 diabetes and ...

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

The first clinical trial of its kind found the weekly semaglutide jab cuts the amount people drink in one day by 40 per cent ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Rapid weight loss affects muscle mass and can increase the risk of osteoporosis. But now there is good news for people taking weight loss medication who may be at risk. A new study indicates that the ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...